Circle Pharma Declares First Patients Dosed in Phase 1 Clinical Trial

Circle Pharma, Inc., a company focused on finding and creating new macrocycle therapies, disclosed that the initial group of patients has been given doses in the phase 1 study of CID-078, their groundbreaking oral cyclin A/B RxL inhibitor.

The clinical study aims to assess CID-078 in individuals with advanced solid tumors, which may have increased E2F transcription factor activity, like small cell lung cancer, triple negative breast cancer, and ER+ HER-2- breast cancer after treatment with CDK 4/6 inhibitors.

“We are thrilled that the IND for CID-078 was cleared at the end of the 30-day regulatory review period and that CID-078 has now moved into human dosing at a consortium of world class cancer centers. This will allow our investigators to generate clinical proof-of-concept data which will inform CID-078’s potential impact in settings of high unmet medical need as well as validate Circle Pharma’s proprietary MXMO™ macrocycle platform for difficult-to-drug targets in cancer and other serious diseases,” said David J. Earp, JD, Ph.D., CEO of Circle Pharma.

CID-078 is created to specifically block important interactions between proteins cyclins A and B, which play a role in the growth and viability of cancer cells. The research program is based on studies conducted by William G. Kaelin Jr., MD, a Nobel Laureate and Chair of Circle Pharma's Scientific Advisory Board. His work showed synthetic lethality by interfering with these cyclins in situations with abnormal cell cycle regulation and increased E2F activity.